A synthetic route towards 3-(2-pyridyl)-6-(hetero)aryl-1H-pyrazolo[4,3-c]pyridines is described. The key step consists of a microwave-assisted multi-component reaction, including a Sonogashira type cross-coupling of appropriate 5-chloropyrazole-4-carbaldehydes with alkynyl-(hetero)arenes followed by pyridine ring formation of the coupling products in the presence of tert-butylamine, directly affording the title compounds. A congener without substituent at N-1 was accessed via cleavage of a tert-butyl protecting group. Detailed NMR spectroscopic studies ( 1 H, 13 C and 15 N) were undertaken with the obtained compounds. Selected representatives were evaluated for their potential as inhibitors of protein kinases.
Introduction
Cyclin-dependent protein kinases (CDKs) are import drug targets with regard to the treatment of proliferative diseases such as cancer and inflammation. [1] [2] [3] Thus, in the last years considerable effort has been devoted to the development of small molecule inhibitors of CDKs as potential drug candidates for oncology. 1, 2, 4 The purine system became one of the first systematically investigated scaffolds for CDK inhibitors, leading to the discovery of roscovitine (Figure 1 ), which represents one of the first candidates to enter clinical trials. [5] [6] [7] Naturally, the latter compound has inspired further exploration of new CDK inhibitors by variation of the substituents and by repositioning of nitrogen atoms on the purine scaffold. Thus, various congeners containing 2-5 nitrogen atoms in the bicyclic core have been considered. In the course of these investigations, representatives of four classes of bioisosteres revealed improved biological properties, namely pyrazolo [4,3-d] pyrimidines (A), pyrazolo [1,5-a] pyrimidines (B), pyrazolo [1,5-a] pyridines (C) and pyrazolo [1,5-a] [1, 3, 5] triazines (D) (Figure 1 ). 8, 9 In view of this we became interested in somewhat related compounds of type E, characterized by a pyrazolo [4,3-c] pyridine core and carrying at least one pyridyl substituent in order to provide a slightly basic side-chain ( Figure 1 ). 
Results and Discussion
Synthetic study Recently, we have presented a novel and general access to the synthesis of pyrazolo [4,3-c] pyridines via Sonogashira cross-coupling of 5-chloropyrazole-4-carbaldehydes and subsequent pyridine ring closure of the resulting 5-alkynylpyrazole-4-carbaldehydes in the presence of tertbutylamine as the nitrogen source. 10 According to this approach, the envisaged synthetic pathway to the target compounds of type 6 and 7, respectively, is presented in Scheme 1. β-Keto ester 2, obtained via condensation of 2-acetylpyridine (1) with diethyl carbonate, should be transformed into the appropriate pyrazolone 3 and the latter by Vilsmeier reaction -with concomitant transformation of the OH group into a chloro functionality -into the corresponding N-protected 5-chloropyrazole-4-carbaldehyde 4. Subsequently, Sonogashira coupling reaction with terminal alkynes should generate the respective alkyne intermediate 5, which in the presence of tertbutylamine should undergo ring closure into the respective pyrazolo[4,3-c]pyridine 6. Optional removal of the protecting R 1 should provide congeners of type 7 unsubstituted at pyrazole N-1.
Scheme 1.
Envisaged synthetic route to the target compounds 6 and 7.
Initially, employment of a para-methoxybenzyl (PMB) protecting group (R 1 = PMB) was considered for further procedure, because PMB is an approved protecting group for pyrazoles and condensed pyrazoles, and several examples show more or less uncomplicated cleavage by treatment with TFA. [11] [12] [13] Unfortunately, an orienting Vilsmeier-Haak formylation 14 applied to 2-(4-methoxybenzyl)-2,4-dihydro-3H-pyrazol-3-one demonstrated that the PMB group does not survive the harsh conditions of this reaction. For this reason, the more stable but harder to cleave benzyl group and the even less vulnerable methyl group were considered as possible R 1 protecting groups. The synthesis of pyrazolones 3 (3a: R 1 = Me, 3b. R 1 = PhCH 2 ) was accomplished via reaction of 3-oxoester 2 -the latter obtained by condensation of 2-acetylpyridine (1) with diethyl carbonate -with methylhydrazine and benzylhydrazine, respectively. The high electron density at position 4 of the pyrazole system of compounds 3a,b permits smooth Vilsmeier-Haack formylation (DMF/POCl 3 ), whereas due to the presence of excessive POCl 3 the OH-group (the tautomeric equivalent of pyrazolone C=O) is simultaneously transformed into a chloro function to afford 5-chloropyrazole-4-carbaldehydes 4a,b in good yields. 15 In recent studies we have shown that 1-substituted 5-chloropyrazole-4-carbaldehydes Surprisingly, aldehydes 4a,b proved to be fairly inert in cross-couplings with phenylacetylene or 2-ethynylpyridine under standard conditions. Neither did variation of the Pd catalyst and/or solvent, nor applying the reaction under microwave assistance, lead to satisfying results, i.e. to the formation of coupling products 5 in acceptable yields. However, a breakthrough was achieved when Sonogashira coupling and subsequent pyridine ring closure to bicycles 6 were carried out as a one-pot multi-component reaction. In order to prepare N-unsubstituted congeners, for instance 7a, which could be used in biological tests, removal of the N-1 protecting group in the corresponding compounds 6 was necessary. It is known from the literature that N-methyl groups can be removed from N-1 of pyrazoles or condensed pyrazoles by melting the N-methyl derivatives with anhydrous pyridine hydrochloride. 20 However, when compounds 6a-c were subjected to such reaction conditions (210 °C) in most cases complex reaction mixtures resulting from decomposition reactions were obtained. Removal of the benzyl group of 6d was attempted by various hydrogenolytic methods (Pd/C or Pd(OH) 2 / formic acid / ammonium formate; Pd/C, H 2 , MeOH; Pd/C, 1,4-cyclohexadiene, EtOH). [21] [22] [23] Either unreacted starting material was obtained or decomposition was observed. As benzylic protecting groups alternatively can be removed by oxidative methods, also the system KOt-Bu/DMSO 24 was applied, but no reaction was observed. Furthermore, treatment with TFA, HBr or AlCl 3 in toluene was not successful. As an alternative, the tert-butyl protecting group was considered; this has been successfully employed in pyrazole chemistry. 25 Thus, pyrazolone 3c (R 1 = tert-butyl) was prepared from 2 and tert-butylhydrazine and subsequently converted into aldehyde 4c (R 1 = tert-butyl, Scheme 1), however in low yields. Multi-component reaction with 3-alkynylpyridine or 3-alkynylthiophene, respectively, afforded bicycles 6e and 6f. The deprotection of 6e was tried under different conditions, for instance in TFA, TFA-H 2 O (rt and afterwards at 120 °C), as well in HCOOH, HCl, at rt and reflux, where no reaction was observed. Finally, the removal of the protecting group was accomplished by treatment of 6e with conc. H 2 SO 4 affording the target compound 7a (Scheme 2).
NMR Spectroscopic investigations
Pyrazolones of type 3 are capable of prototropic tautomerism. Due to the low solubility of 7a in chloroform the NMR spectra were recorded of a DMSO-d 6 solution. In principle, for 7a annular prototropic tautomerism at the pyrazole ring is possible (proton attached to N-1 or N-2). Moreover, the flexible proton theoretically could be also located at N-5 or at the pyridine N-atom of the 3-substituent, however the latter possibilities can be definitely ruled out considering the 15 N chemical shifts of the concerning nitrogen atoms.
Nevertheless, a distinct NOE between the acidic proton (δ 13.89 ppm) and H-7 (δ 8.17 ppm) unequivocally confirms preference for the N1-H form (Figure 3, right) . Moreover, the similarity of 1 H, 13 Due to the low solubility of 7a in chloroform the NMR spectra were recorded of a DMSO-d 6 solution. In principle, for 7a annular prototropic tautomerism at the pyrazole ring is possible (proton attached to N-1 or N-2). Moreover, the flexible proton theoretically could be also located at N-5 or at the pyridine N-atom of the 3-substituent, however the latter possibilities can be definitely ruled out considering the 15 N chemical shifts of the concerning nitrogen atoms.
Nevertheless, a distinct NOE between the acidic proton (δ 13.89 ppm) and H-7 (δ 8.17 ppm) unequivocally confirms preference for the N1-H form (Figure 3, right) . Moreover, the similarity of 1 H, 13 
Biological tests
Our aim was to prepare a new scaffold of protein kinase inhibitors. Therefore, the biological activity of prepared compounds 6 and 7 was assayed as described previously. 28 The compounds have been tested in kinase inhibition assays for their inhibitory potency towards recombinant CDK2, CDK9, CK2 and c-Abl, and for their cytotoxicity against various cancer cell lines. None of the tested compounds proved biological activity, but we consider these results to be preliminary and further modification of the molecules are necessary to identify first hits amongst our pyrazolo [4,3-c] pyridines. Most known kinase inhibitors are heterocyclic organic molecules that act like ATP competitors, interacting through one to three hydrogen bonds with the hinge region of the kinase. 1 Our future work will focus on modifications that would create typical Hbond donor-acceptor motif and on modifications increasing the polarity (solubility).
Experimental Section
General. 29 The elemental analyses were performed at the microanalytical laboratory (Faculty of Chemistry) and were in good agreement (+/-0.4%) with the calculated values. For the microwave reaction system an Anton Paar Synthos 3000 was employed. Light petroleum refers to the fraction with boiling point 40-65 °C. Yields are not optimized.
Synthesis of 2-methyl-5-(2-pyridyl)-2,4-dihydro-3H-pyrazol-3-one (3a)
. 30 To a solution of ethyl 3-oxo-3-(2-pyridyl)propionate (2) 
Synthesis of 2-(phenylmethyl)-5-(2-pyridyl)-2,4-dihydro-3H-pyrazol-3-one (3b).
Under stirring at 0 °C, benzylhydrazine (1.22 g, 10.00 mmol) was added dropwise to ethyl 3-oxo-3-(2-pyridyl)propionate (2) 2-(1,1-dimethylethyl)-5-(2-pyridyl)-2,4-dihydro-3H-pyrazol-3-one (3c) . tertButylhydrazine hydrochloride (7.85 g, 0.061 mol) was dissolved in acetic acid (20 mL) and ethyl 3-oxo-3-(2-pyridyl)propionate (2) (9.8 g, 0.05 mol) was added. The mixture was stirred at 110 °C for 3 h. The reaction mixture was cooled to rt and neutralized with aqueous sodium hydrogen carbonate solution and then exhaustively extracted with ethyl acetate. The combined organic layers were washed with brine and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure and the residue was purified by column chromatography using ethyl acetate/light petroleum (2:1 v/v) as the eluent. The pyrazolone 3c was isolated as a pale yellow solid (7.10 g, 65%), mp 179-180 °C. 
Synthesis of 5-chloro-3-(2-pyridyl)-1H-pyrazole-4-carbaldehydes (4). General procedure.
Under anhydrous conditions POCl 3 (2.60 mL, 4.29 g, 28.00 mmol) was carefully added dropwise to dry DMF (0.98 mL, 936 mg, 12.80 mmol) under cooling. Then the appropriate 5-(2-pyridyl)-2,4-dihydro-3H-pyrazol-3-one (3) (4.00 mmol) was added and the mixture was heated to reflux for 2 h. The reaction mixture was then cooled to room temperature and the dark coloured solution was poured into ice water with stirring. The reaction mixture was neutralized with 1N NaOH until a precipitate formed and then extracted with ethyl acetate (3 × 10 mL). The combined organic phases were dried (Na 2 SO 4 ), the solvent was removed under reduced pressure, and the residue was purified by column chromatography using ethyl acetate/light petroleum; 1:4 v/v. 
5-Chloro-1-methyl-3-(2-pyridyl)-1H-pyrazole-4-carbaldehyde (4a

Biological tests
Kinase inhibition assays. CDK2/Cyclin E kinase was produced in Sf9 insect cells via baculoviral infection and purified on a NiNTA column (Qiagen). CDK5/p35, CDK7Cyclin H/MAT1 and CDK9/Cyclin T1 were purchased from ProQinase GmbH. The kinase reactions were assayed with 1 mg/mL histone H1 (for CDK2 and CDK5) or (YSPTSPS) 2 and finally air-dried. Kinase inhibition was quantified using a FLA-7000 digital image analyzer (Fujifilm). The concentration of the test compounds required to decrease the CDK activity by 50 % was determined from dose-response curves and designated as IC 50 .
28
Cell maintenance and cytotoxicity assays. The cytotoxicity of the studied compounds was determined using cell lines of different histological origin as described earlier. 28 Briefly, the cells were assayed with compounds using three-fold dilutions in triplicate. Treatment lasted for 72 h, followed by addition of Calcein AM solution, and measurement of the fluorescence of live cells at 485 nm/538 nm (ex/em) with a Fluoroskan Ascent microplate reader (Labsystems). IC 50 (the drug concentration that reduced the number of viable cells to 50 %) values were determined from the dose-response curves.
